Hsbc Holdings PLC Takes $5.02 Million Position in Enovis Corporation $ENOV

Hsbc Holdings PLC purchased a new position in Enovis Corporation (NYSE:ENOV) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 248,195 shares of the company’s stock, valued at approximately $5,016,000. Hsbc Holdings PLC owned 0.43% of Enovis at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. AQR Capital Management LLC increased its position in shares of Enovis by 12.5% in the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock valued at $2,363,000 after buying an additional 7,072 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Enovis by 37.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock valued at $10,226,000 after buying an additional 73,116 shares in the last quarter. Empowered Funds LLC lifted its position in shares of Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after buying an additional 749 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the period. Finally, Amundi grew its stake in Enovis by 24,405.0% in the 2nd quarter. Amundi now owns 9,802 shares of the company’s stock valued at $328,000 after acquiring an additional 9,762 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Trading Up 0.3%

Shares of ENOV opened at $24.91 on Friday. Enovis Corporation has a 52-week low of $19.14 and a 52-week high of $34.28. The stock has a market cap of $1.44 billion, a PE ratio of -1.29 and a beta of 1.34. The firm’s fifty day moving average is $25.60 and its two-hundred day moving average is $24.25. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. The business had revenue of $582.78 million during the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. UBS Group reissued a “buy” rating and set a $51.00 target price (up from $50.00) on shares of Enovis in a research note on Tuesday, July 28th. Wall Street Zen downgraded shares of Enovis from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Enovis in a research note on Friday, August 7th. Finally, Wells Fargo & Company lowered their price objective on Enovis from $40.00 to $39.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.29.

Insider Buying and Selling

In other Enovis news, insider Oliver Engert acquired 1,200 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was bought at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the acquisition, the insider owned 51,840 shares in the company, valued at approximately $1,120,780.80. The trade was a 2.37% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. In the last three months, insiders have bought 4,200 shares of company stock valued at $92,084. 2.90% of the stock is currently owned by corporate insiders.

Enovis Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.